Filana Therapeutics
FLNA
47 hedge funds and large institutions have $55.6M invested in Filana Therapeutics in 2016 Q2 according to their latest regulatory filings, with 7 funds opening new positions, 12 increasing their positions, 10 reducing their positions, and 4 closing their positions.
75% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 4
20% more repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 10
7% more funds holding
Funds holding: 44 → 47 (+3)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
4% less capital invested
Capital invested by funds: $57.9M → $55.6M (-$2.27M)
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $90K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
First Eagle Investment Management
New York
|
+$2.08M |
| 2 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$227K |
| 3 |
6CM
683 Capital Management
New York
|
+$172K |
| 4 |
Renaissance Technologies
New York
|
+$165K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$106K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
-$1.58M |
| 2 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
-$1.57M |
| 3 |
JGC
J. Goldman & Co
New York
|
-$1.08M |
| 4 |
GIM
Granahan Investment Management
Waltham,
Massachusetts
|
-$47.9K |
| 5 |
D.E. Shaw & Co
New York
|
-$34.8K |
FLNA Hedge Fund Activity: Q2 2016 in Review
47 of the 3,756 institutional investors tracked by Wall St. Rank reported a position in Filana Therapeutics (FLNA) for Q2 2016, worth a combined $55.6M — down 3.9% from $57.9M a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new FLNA positions and 4 closed out — a net gain of 3 holders — while 12 added to existing stakes and 10 trimmed.
The largest buyer was First Eagle Investment Management, adding an estimated $2.08M. The largest seller was Nantahala Capital Management, cutting an estimated $1.58M.
- 47 institutional investors held Filana Therapeutics (FLNA) as of Q2 2016, up from 44 in Q1 2016.
- Funds reported $55.6M of Filana Therapeutics stock for Q2 2016, down 3.9% quarter-over-quarter.
- 7 funds opened new Filana Therapeutics positions in Q2 2016 and 4 closed out, a net change of +3 holders.
- The largest Filana Therapeutics buyer in Q2 2016 was First Eagle Investment Management, an estimated $2.08M added.
- The largest Filana Therapeutics seller in Q2 2016 was Nantahala Capital Management, an estimated $1.58M sold.
Based on aggregated 13F filings for Q2 2016.